PARSIPPANY, N.J. and ANN ARBOR, Mich., Dec. 16 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc [GSK] and NanoBio Corporation today announced an exclusive licensing agreement in the United States and Canada for the over-the-counter (OTC) use of NB-001, a novel, patented compound representing the next advance in the treatment of cold sores. Developed by NanoBio, NB-001 provides significant antimicrobial activity against the virus that causes cold sores, herpes labialis.
NanoBio has completed two Phase 2 clinical trials of NB-001, demonstrating clear efficacy and a good safety profile in patients and plans to enter Phase 3 testing soon.
"I am pleased to announce this partnership with GSK as it will enable the development and commercialization of NB-001 to its fullest potential," said James R. Baker, Jr., MD, NanoBio's CEO and founder. "GSK's demonstrated leadership in developing and marketing consumer healthcare products, including the leading product for the treatment of herpes labialis, makes them the ideal partner for NB-001. On a broader scale, this partnership further validates the promise of our proprietary platform technology, and its potential use in a wide range of dermatological and anti-infective applications."
NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.
GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
CONTACT: Media Relations: GSK Consumer Healthcare, Malesia Dunn,
+1-412-200-3544, Jennifer May, +1-412-200-3729; NanoBio Corporation, John
Coffey, +1-734-302-9107; Schwartz Communications, Laura Coluci or Benjamin
Navon, +1-781-684-0770
Web site: http://www.gsk.com/
